Welcome to our dedicated page for Greenwich Lifesciences SEC filings (Ticker: GLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Greenwich LifeSciences, Inc. (GLSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, proxy statements, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detail on corporate governance, auditor changes, shareholder voting outcomes, and other matters that complement the company’s clinical and regulatory news about GLSI-100 and the FLAMINGO-01 trial.
Form 8-K filings capture material events such as the July 24, 2025 change in independent registered public accounting firm from RBSM LLP to MaloneBailey LLP, including discussion of prior audit opinions, internal control material weaknesses referenced from the company’s periodic reports, and the absence of specified disagreements with the former auditor. Another 8-K dated December 18, 2025 reports the results of the 2025 Annual Meeting of Stockholders, detailing the election of directors and the ratification of MaloneBailey LLP as the auditor for the fiscal year ended December 31, 2025.
The DEF 14A definitive proxy statement for the 2025 Annual Meeting describes the proposals presented to stockholders, the record date, meeting logistics, and the matters subject to a vote, such as board elections and auditor ratification. Together, these filings outline how Greenwich LifeSciences manages shareholder meetings, voting procedures, and audit oversight while it advances its clinical program.
On Stock Titan, GLSI filings are paired with AI-powered tools that help summarize key points from lengthy documents, highlight important sections, and make it easier to understand topics like auditor changes, board composition, and voting results. Investors can use this page to quickly review Greenwich LifeSciences’ official statements, monitor governance developments over time, and connect these disclosures with the company’s ongoing work on GLSI-100 and the FLAMINGO-01 Phase III trial.
Greenwich LifeSciences, Inc. director, CEO and CFO Snehal Patel, who is also a 10% owner, reported buying additional company stock. On January 13, 2026, he purchased 1,800 shares of common stock at a price of $29.83 per share. Following this open-market purchase, he beneficially owns 5,604,102 common shares, held in direct ownership.
Greenwich LifeSciences insider activity: Snehal Patel, who serves as CEO, CFO, director and a 10% owner of Greenwich LifeSciences, Inc., reported buying additional company stock. On 01/12/2026, he purchased 2,900 shares of common stock in an open market transaction coded as a "P" transaction at a price of $27.54 per share.
Following this purchase, Patel directly beneficially owned 5,602,302 shares of Greenwich LifeSciences common stock. The filing reflects direct ownership, with no indirect ownership reported in this transaction.
Greenwich LifeSciences, Inc. reported the results of its Annual Meeting of Stockholders held on December 18, 2025. A total of 8,944,615 shares of common stock were represented in person or by proxy, satisfying quorum requirements.
Stockholders elected all five director nominees — David McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, M.D., and Kenneth Hallock — to serve until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Each nominee received over 7.1 million votes “for,” with no votes “against,” and varying abstentions, alongside broker non-votes.
Stockholders also ratified the appointment of MaloneBailey LLP as the company’s independent registered public accounting firm for the fiscal year ended December 31, 2025, with 8,908,299 votes “for,” 31,459 “against,” and 4,857 “abstain.”
Greenwich LifeSciences, Inc. (GLSI)Snehal Patel received a grant of 100,000 stock options on 11/13/2025. These options have an exercise price of $8.2 per share and are exercisable into 100,000 shares of common stock, with an expiration date of 11/13/2035. Following this grant, Patel beneficially owns 2,347,462 derivative securities directly.
Greenwich LifeSciences (GLSI) reported Q3 2025 results with no revenue and a net loss of
Cash was
Management disclosed substantial doubt about the company’s ability to continue as a going concern and reported material weaknesses in internal controls. The Phase III Flamingo‑01 trial of GLSI‑100 continues as the core operating focus.
Greenwich LifeSciences (GLSI) reported an insider open‑market purchase. Snehal Patel acquired 10,600 shares of common stock at $8.43 on 11/07/2025. After this transaction, his beneficial ownership stands at 5,583,502 shares, held directly.
Patel is the company’s CEO, CFO, a director, and a 10% owner. The report reflects one reporting person and lists the transaction in Table I; no derivative transactions are shown in Table II.
Greenwich LifeSciences (GLSI): Insider purchase reported. CEO, CFO and Director Snehal Patel, a 10% owner, bought 2,300 shares of common stock on 10/31/2025 at $9.26 per share. Following this transaction, he beneficially owned 5,572,902 shares, reported as direct ownership.
Greenwich LifeSciences will hold its Annual Meeting on December 18, 2025 at 9:00 a.m. local time in New York to elect five directors and ratify MaloneBailey LLP as independent auditor for fiscal 2025.
The record date is October 28, 2025, with 13,854,539 shares outstanding; a quorum requires 6,927,270 shares represented. Directors are elected by a plurality of votes cast, while auditor ratification requires a majority of shares present and entitled to vote.
Ownership is concentrated: CEO Snehal Patel beneficially owns 6,074,953 shares (
FAQ
What is the current stock price of Greenwich Lifesciences (GLSI)?
What is the market cap of Greenwich Lifesciences (GLSI)?
